Table 1.
Patient characteristics
| Characteristic (n = 43 patients) | Value* |
|---|---|
| Median age, range | 65 (47–79) years |
| Median weight, range | 87 (63–120) kg |
| Median PSA level, range at imaging | 10.3 (2.62–110) ng/mL |
| Risk group classification based on D’Amico’s classification system [13] | |
| Number of patients at intermediate risk | 14 (32.5%) |
| Number of patients at high risk | 29 (67.5%) |
| Number of patients with > 5% risk of lymph node involvement according to Briganti et al. [14] | 37 (86%) |
| Gleason score** | |
| 6 | 2 (4.6%) |
| 7–8 | 33 (76.8%) |
| 9–10 | 8 (18.6%) |
| ISUP grade (2014 ISUP grading system) | |
| 1 | 2 (4.6%) |
| 2 | 14 (32.6%) |
| 3 | 8 (18.6%) |
| 4 | 5 (11.6 %) |
| 5 | 14 (32.6 %) |
| Clinical T stage | |
| cT1-2a | 27 (62.8%) |
| cT2b | 7 (16.3%) |
| cT2c | 4 (9.3%) |
| cT3-4 | 5 (11.6%) |
ISUP = International Society of Urological Pathology
*Values are reported as numbers of patients, with percentages of patients in brackets, unless otherwise indicated
**Biopsy Gleason score for 16 patients and surgery Gleason score for 27 patients